TATES I ATENT AND TRADEMARK OFFICE UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov DEC 2 6 2006 FIRST NAMED INVENTOR ATTORNEY DOCKET NO. APPLICATION NO. CONFIRMATION NO. 10/520,698 08/02/2005 Andre Francois Gorenflot I-2002.010 US 2601 11/02/2006 **EXAMINER** 31846 7590 INTERVET INC. GANGLE, BRIAN J PATENT DEPARTMENT ART UNIT PAPER NUMBER **PO BOX 318** MILLSBORO, DE 19966-0318 1645

DATE MAILED: 11/02/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

RECEIVED BY PATENT DEPT.

NOV - 6 2006

INTERVET INC.
MILLSBORO, DELAWARE

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, DC 2023' WWW.USDIO.GOV

APPLICATION NO./CONTROL NO. 10/520,698

TOUNG DATE

FIRST NAMED INVENTOR IPATENT IN REEXAMINATION

ATTORNEY DOCKET NO.

EXAMINER

Brian J. Gangle

ART UNIT

PAPER

1645

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

The specification contains amino acid sequences which do not have the requisite sequence identifiers (see for example, Table 1).

Since the response appears to be <u>bona fide</u>, but through an apparent oversight or inadvertence failed to provide a complete response, APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R.. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brian J. Gangle whose telephone number is (571) 272 - 1181.

ROBERT A. ZEMAN PRIMARY EXAMINER

^pplication No.: <u>10/520,698</u>

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

X	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	2. This application does not contain, as a separate part of the disclosure on paper copy, a Sequence Listing: as required by 37 C.F.R. 1.821(c).
	3. A copy of the Sequence Listing in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the Sequence Listing in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up Raw Sequence Listing.
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the Sequence Listing is not the same as the computer readable from of the Sequence Listing as required by 37 C.F.R. 1.821(e).
X	7. Other: The specification contains amino acid sequences which do not have the requisite sequence identifiers (see, for example, Table 1).
Applicant Must Provide:	
X	An initial or substitute computer readable form (CRF) copy of the Sequence Listing.
X	An initial or substitute paper copy of the Sequence Listing, as well as an amendment directing its entry into the specification.
X	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For	questions regarding compliance to these requirements, please contact:
For	Rules Interpretation, call (703) 308-4216 CRF Submission Help, call (703) 308-4212 entIn Software Program Support Technical Assistance
	PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY



Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop: Sequence Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on <u>December 20, 2006</u>

Date

Diane Payne

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Applicant: Gorenflot, A.F. et al.

Serial No: 10/520,698

§ 371 File Date: August 2, 2005

Confirmation No: 2601 Customer No.: 31846

Attorney Docket: I-2002.010 US

Receipt acknowledged of the following documents in the above-identified application:

Transmittal Letter for Substitute Sequence Listing (4 pages)

Paper copy of the Substitute Sequence Listing (3 pages)

CRF of the Substitute Sequence Listing (2 CDs)

Copy of Notice to Comply with Requirement of November 2, 2006 (3 pages)

Self-addressed post card (1)